Tag: Lord Mawhinney

The below Parliamentary question was asked by Lord Mawhinney on 2016-01-27.

To ask Her Majesty’s Government what is their estimate of how long it would take for research-led treatment to eradicate Lyme disease from the UK if resource provision were no issue.

Lord Prior of Brampton

It is not practical to eradicate Lyme disease in the United Kingdom through treatment of human cases, therefore no cost estimate has been made. The disease is endemic in much of the small mammal and bird population in the UK, and is spread to humans by the bite of infected ticks which have fed on these animals. The number of human cases can be reduced by raising public awareness of how to avoid tick bites, and by environmental measures in public places to reduce the long grass and scrub which harbour ticks.

The number of laboratory confirmed cases of Lyme disease in England and Wales varies annually, in 2013 there were 878 and in 2014 there were 730, but the majority of diagnoses are made clinically by general practitioners and those figures are not recorded. Patients with late or complicated Lyme disease may be diagnosed in a variety of specialist clinics, and the numbers are not recorded. Based on the clinical information supplied with the laboratory request, only a small proportion of the annual number of cases fall into this category.

The Health Protection Research Unit of the University of Liverpool in partnership with Public Health England (PHE) has funding from the National Institute of Health Research for research into Lyme disease, covering diagnostics and biomarkers and public awareness. PHE is working on clinically linked studies for diagnostics with the Czech Republic, as no single centre in the UK has sufficient patients for a suitable study; funding for this work is not yet in place. PHE undertakes limited studies on ticks and Lyme disease in the UK. The Research Councils fund some additional work on ticks and the environment.

The below Parliamentary question was asked by Lord Mawhinney on 2016-09-14.

To ask Her Majesty’s Government how many provider NHS trusts achieved an improvement in operating efficiency of four per cent or more without aggravating their debt position in the last financial year.

Baroness Chisholm of Owlpen

There is no nationally agreed metric for operating efficiency. However, an annual efficiency requirement is built into the tariff uplift calculation that is used by commissioners in their contract negotiation with providers. In 2015-16 this efficiency requirement was 3.5% over 2014-15. Therefore, we can assume that organisations are delivering this efficiency if they improve their financial position based on these efficiency adjusted prices.

In February 2016, the Department published Lord Carter’s Operational productivity and performance in English NHS acute hospitals: Unwarranted variations report, a review of efficiency in hospitals which provided details of how operational savings can be achieved. A copy of the report is attached. This programme, along with ‎additional funding provided by the government, will help reduce deficits in this year and bring the sector back into financial balance in future years.

The National Health Service will receive additional funding of £10 billion per year by the end of the current Spending Review period, with £3.8 billion provided in 2016-17 alone. From this £3.8 billion, we have created a £2.1 billion Sustainability and Transformation Fund that will help providers move to a sustainable financial footing.

NHS Improvement’s 2016-17 quarter 1 performance report confirmed that things are improving in this year, with lower levels of deficit, fewer trusts reporting a deficit and savings on agency staff.

The below Parliamentary question was asked by Lord Mawhinney on 2016-01-27.

To ask Her Majesty’s Government what is their estimate of how many people in the UK have Lyme disease.

Lord Prior of Brampton

It is not practical to eradicate Lyme disease in the United Kingdom through treatment of human cases, therefore no cost estimate has been made. The disease is endemic in much of the small mammal and bird population in the UK, and is spread to humans by the bite of infected ticks which have fed on these animals. The number of human cases can be reduced by raising public awareness of how to avoid tick bites, and by environmental measures in public places to reduce the long grass and scrub which harbour ticks.

The number of laboratory confirmed cases of Lyme disease in England and Wales varies annually, in 2013 there were 878 and in 2014 there were 730, but the majority of diagnoses are made clinically by general practitioners and those figures are not recorded. Patients with late or complicated Lyme disease may be diagnosed in a variety of specialist clinics, and the numbers are not recorded. Based on the clinical information supplied with the laboratory request, only a small proportion of the annual number of cases fall into this category.

The Health Protection Research Unit of the University of Liverpool in partnership with Public Health England (PHE) has funding from the National Institute of Health Research for research into Lyme disease, covering diagnostics and biomarkers and public awareness. PHE is working on clinically linked studies for diagnostics with the Czech Republic, as no single centre in the UK has sufficient patients for a suitable study; funding for this work is not yet in place. PHE undertakes limited studies on ticks and Lyme disease in the UK. The Research Councils fund some additional work on ticks and the environment.

The below Parliamentary question was asked by Lord Mawhinney on 2016-09-14.

To ask Her Majesty’s Government whether they envisage any form of public consultation before they decide their negotiating position, once Article 50 has been invoked, on those relationships with Ireland that fall outside EU competence.

Lord Bridges of Headley

The Department for Exiting the EU will be conducting the UK’s negotiations to leave the European Union in support of the Prime Minister. We will be working closely with Parliament, devolved administrations, and a wide range of other interested parties.

Our relationship with Ireland is unique and we have already engaged extensively with Northern Ireland and the Republic of Ireland. The Prime Minister and the Taoiseach met in London on 26 July and the Secretary of State for Exiting the EU visited both Belfast and Dublin in early September to engage with government and business stakeholders.

We look forward to working closely with the Irish Government and other key stakeholders as we develop our approach, and to make the most of the opportunities for both countries.

The below Parliamentary question was asked by Lord Mawhinney on 2016-01-27.

To ask Her Majesty’s Government what is their estimate of how much money would be needed to eradicate Lyme disease from the UK.

Lord Prior of Brampton

It is not practical to eradicate Lyme disease in the United Kingdom through treatment of human cases, therefore no cost estimate has been made. The disease is endemic in much of the small mammal and bird population in the UK, and is spread to humans by the bite of infected ticks which have fed on these animals. The number of human cases can be reduced by raising public awareness of how to avoid tick bites, and by environmental measures in public places to reduce the long grass and scrub which harbour ticks.

The number of laboratory confirmed cases of Lyme disease in England and Wales varies annually, in 2013 there were 878 and in 2014 there were 730, but the majority of diagnoses are made clinically by general practitioners and those figures are not recorded. Patients with late or complicated Lyme disease may be diagnosed in a variety of specialist clinics, and the numbers are not recorded. Based on the clinical information supplied with the laboratory request, only a small proportion of the annual number of cases fall into this category.

The Health Protection Research Unit of the University of Liverpool in partnership with Public Health England (PHE) has funding from the National Institute of Health Research for research into Lyme disease, covering diagnostics and biomarkers and public awareness. PHE is working on clinically linked studies for diagnostics with the Czech Republic, as no single centre in the UK has sufficient patients for a suitable study; funding for this work is not yet in place. PHE undertakes limited studies on ticks and Lyme disease in the UK. The Research Councils fund some additional work on ticks and the environment.

The below Parliamentary question was asked by Lord Mawhinney on 2016-10-13.

To ask Her Majesty’s Government whether it is their intention to amalgamate local primary care centres into larger units; and if so, when.

Lord Prior of Brampton

As part of the New Care Models Programme, NHS England is supporting local health and care commissioners and providers to come together to improve the health and care they provide. This includes the development of population-based care models known as integrated Primary and Acute Care Systems and Multispecialty Community Providers (MCPs). Where and how to develop new care models are decisions taken by local partnerships, in response to local conditions. The Programme is not directing or requiring the amalgamation of primary care centres.

There are 14 MCP vanguards, with a single organisation accountable for joined-up General Practitioner (GP) and community services and some specialist care, mental health services, and social care for a defined population. The building blocks of a MCP are the ‘care hubs’ of integrated teams. Each typically serves a community of around 30,000-50,000 people. These hubs are the practical, operational level of any model of accountable care provision. The wider the scope of services included in the MCP, the more hubs you may need to connect together to create sufficient scale. All 14 MCP vanguards now serve a minimum population of around 100,000.

The majority of GP practices are already working in practice groups or federations. This provides opportunities to expand services, stabilise practice income and work at scale, which has benefits for patients, practices and the wider system. These include economies of scale, quality improvement, workforce development, enhanced care and new services, resilience and system partnerships.

A new voluntary MCP contract will be introduced from April 2017, to integrate general practice services with community services and wider healthcare services. Measures from the GP Access Fund and vanguard sites that are currently piloting this approach, will be learned from to support mainstreaming of proven service improvements across all practices, and funding will be provided for local collaborations to support practices to implement new ways of working.

The below Parliamentary question was asked by Lord Mawhinney on 2016-01-27.

To ask Her Majesty’s Government what assessment they have made of which medical institutions in the UK are in the forefront of research into, and treatment of, Lyme disease.

Lord Prior of Brampton

It is not practical to eradicate Lyme disease in the United Kingdom through treatment of human cases, therefore no cost estimate has been made. The disease is endemic in much of the small mammal and bird population in the UK, and is spread to humans by the bite of infected ticks which have fed on these animals. The number of human cases can be reduced by raising public awareness of how to avoid tick bites, and by environmental measures in public places to reduce the long grass and scrub which harbour ticks.

The number of laboratory confirmed cases of Lyme disease in England and Wales varies annually, in 2013 there were 878 and in 2014 there were 730, but the majority of diagnoses are made clinically by general practitioners and those figures are not recorded. Patients with late or complicated Lyme disease may be diagnosed in a variety of specialist clinics, and the numbers are not recorded. Based on the clinical information supplied with the laboratory request, only a small proportion of the annual number of cases fall into this category.

The Health Protection Research Unit of the University of Liverpool in partnership with Public Health England (PHE) has funding from the National Institute of Health Research for research into Lyme disease, covering diagnostics and biomarkers and public awareness. PHE is working on clinically linked studies for diagnostics with the Czech Republic, as no single centre in the UK has sufficient patients for a suitable study; funding for this work is not yet in place. PHE undertakes limited studies on ticks and Lyme disease in the UK. The Research Councils fund some additional work on ticks and the environment.

The below Parliamentary question was asked by Lord Mawhinney on 2016-10-13.

To ask Her Majesty’s Government whether it is (1) their policy, or (2) the policy of NHS England, that primary care centres should be amalgamated into larger units.

Lord Prior of Brampton

As part of the New Care Models Programme, NHS England is supporting local health and care commissioners and providers to come together to improve the health and care they provide. This includes the development of population-based care models known as integrated Primary and Acute Care Systems and Multispecialty Community Providers (MCPs). Where and how to develop new care models are decisions taken by local partnerships, in response to local conditions. The Programme is not directing or requiring the amalgamation of primary care centres.

There are 14 MCP vanguards, with a single organisation accountable for joined-up General Practitioner (GP) and community services and some specialist care, mental health services, and social care for a defined population. The building blocks of a MCP are the ‘care hubs’ of integrated teams. Each typically serves a community of around 30,000-50,000 people. These hubs are the practical, operational level of any model of accountable care provision. The wider the scope of services included in the MCP, the more hubs you may need to connect together to create sufficient scale. All 14 MCP vanguards now serve a minimum population of around 100,000.

The majority of GP practices are already working in practice groups or federations. This provides opportunities to expand services, stabilise practice income and work at scale, which has benefits for patients, practices and the wider system. These include economies of scale, quality improvement, workforce development, enhanced care and new services, resilience and system partnerships.

A new voluntary MCP contract will be introduced from April 2017, to integrate general practice services with community services and wider healthcare services. Measures from the GP Access Fund and vanguard sites that are currently piloting this approach, will be learned from to support mainstreaming of proven service improvements across all practices, and funding will be provided for local collaborations to support practices to implement new ways of working.

The below Parliamentary question was asked by Lord Mawhinney on 2016-03-17.

To ask Her Majesty’s Government how information is (1) collected, and (2) managed, to protect the dignity of patients who receive pharmacy services in retail outlets, under the Standards for registered pharmacies, Principle 1.

Lord Prior of Brampton

Pharmacy owners and superintendent pharmacists of bodies corporate are responsible for meeting the General Pharmaceutical Council’s standards for registered pharmacies and must decide how best to do so, including managing information to protect the privacy, dignity and confidentiality of patients and the public, within their pharmacies.

There are a number of different ways in which pharmacy professionals and the wider pharmacy team may receive patient information. Information is included on prescriptions, or may be shared by patients when seeking care from a pharmacy. In addition, information may be stored in patient medication records or other records.

Through its inspections, the General Pharmaceutical Council seeks assurance from the pharmacy team about how they maintain the confidentiality, privacy and dignity of patients and the public. These assurances can be provided through a number of different means, for example restricted password access to patient information, appropriate training of staff or making sure patients can have conversations with members of the pharmacy team in private.

All National Health service providers, including community pharmacies, also need to provide information governance assurances to the NHS on an annual basis.

The below Parliamentary question was asked by Lord Mawhinney on 2016-10-13.

To ask Her Majesty’s Government what financial resources they transferred to local authorities in 2015–16 which were designated to be spent on personal social services care; and what is their estimate of how much was spent on the provision of such services.

Lord Bourne of Aberystwyth

Central government does not determine the level of resources spent by local authorities on adult social care. Each local authority will budget for what it expects to require in order to deliver the services required for their population, drawing on funding from local taxes, unhypothecated central government grant and income from fees and charges.

However recognising the pressures on local authorities, the Spending Review 2015 announced that for the rest of the current Parliament, local authorities responsible for adult social care (“ASC authorities”) would be allowed an additional 2 percent on their current council tax referendum threshold to be used entirely for adult social care. 144 of 152 eligible authorities made use of this precept in 2015-16, raising £382 million for social care.

My department publishes data (attached) from local authorities on their spending on all services. Provisional data for 2015-16 suggests that local authorities spent a net figure of £14.4 billion on adult social care in 2015-16.

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/548114/RO_Provisional_Outturn_2015-16_Statistical_Release.pdf

“